Positron emission tomography in esophageal cancer

被引：1

作者：

Kato H. ^{[1
]}

Fukuchi M. ^{[1
]}

Miyazaki T. ^{[1
]}

Nakajima M. ^{[1
]}

Kimura H. ^{[1
]}

Faried A. ^{[1
]}

Sohda M. ^{[1
]}

Fukai Y. ^{[1
]}

Masuda N. ^{[1
]}

Manda R. ^{[1
]}

Ojima H. ^{[1
]}

Tsukada K. ^{[1
]}

Oriuchi N. ^{[2
]}

Endo K. ^{[2
]}

Kuwano H. ^{[1
]}

机构：

[1] Department of General Surgical Science (Surgery I), Gunma University, Graduate School of Medicine, Maebashi 371-8511

[2] Department of Diagnostic Radiology and Nuclear Medicine, Gunma University, Maebashi

来源：

Esophagus | 2005年 / 2卷 / 3期

关键词：

!sup]18[!/sup]F-Fluorodeoxyglucose (FDG); Esophageal cancer; Positron emission tomography (PET); Response to therapy; Staging;

D O I：

10.1007/s10388-005-0053-5

中图分类号：

学科分类号：

摘要：

Positron emission tomography (PET), a functional imaging modality, has provided the transition between the research environment and the clinical environment over the last 10 years. Its primary use is in the field of oncology, where it is being increasingly used in the management of several tumor types including esophageal cancer. 18F-Fluorodeoxyglucose PET (FDG-PET) scans may also be used to distinguish between benign and malignant tumors, to identify different stages of tumor spread, to assess for tumor recurrence, and monitor the response to therapy of malignant diseases. This review aims to outline the current and future roles of PET scanning in the field of esophageal cancer. © Japan Esophageal Society and Springer-Verlag 2005.

引用

页码：111 / 121

页数：10

共 86 条

[1] Pisani P., Parkin D.M., Ferlay J., Estimates of the worldwide mortality from eighteen major cancers in 1985: Implications for prevention and projections of future burden, Int J Cancer, 55, pp. 891-903, (1993)
[2] Levine M.S., Halvorsen R.A., Gore R.M., Levine M.S., Carcinoma of the esophagus, Textbook of Gastrointestinal Radiology, pp. 403-33, (2000)
[3] Levine M.S., Esophageal cancer: Radiologic diagnosis, Radiol Clin N Am, 35, pp. 265-79, (1997)
[4] Daly J.M., Fry W.A., Little A.G., Winchester D.P., McKee R.F., Stewart A.K., Et al., Esophageal cancer: Results of an American College of Surgeons patient care evaluation study, J Am Coll Surg, 190, pp. 562-73, (2000)
[5] Flood W.A., Furastiere A.A., Esophageal cancer, Curr Opin Oncol, 7, pp. 381-6, (1995)
[6] Kuwano H., Kato H., Miyazaki T., Fukuchi M., Masuda N., Nakajima M., Et al., Genetic alterations in esophageal cancer, Surg Today, 35, pp. 7-18, (2005)
[7] Gamliel Z., Incidence, epidemiology, and etiology of esophageal cancer, Chest Surg Clin N Am, 10, pp. 441-50, (2000)
[8] Kato H., Diagnosis and treatment of esophageal neoplasms, Jpn J Cancer Res, 86, pp. 993-1009, (1995)
[9] Block M.I., Patterson G.A., Sundaresan R.S., Bailey M.S., Flanagan F.L., Dehdashti F., Et al., Improvement in staging of esophageal cancer with the addition of positron emission tomography, Ann Thorac Surg, 64, pp. 770-6, (1997)
[10] Luketich J.D., Schauer P.R., Meltzer C.C., Landreneau R.J., Urso G.K., Townsend D.W., Et al., Role of positron emission tomography in staging esophageal cancer, Ann Thorac Surg, 64, pp. 765-9, (1997)

← 1 2 3 4 5 6 7 8 9 →